03Jul2018 CONFIDENTIAL Page  of 
    0(',&$/021,725
0HGLFDO0RQLWRU
25$3(56211(/
'HSDUWPHQW9LFH3UHVLGHQW
3URMHFW0DQDJHU 

03Jul2018 CONFIDENTIAL Page  of 
    dermatologic, hematologic, neurologic, or 
psychiatric disease.
6WXG\7UHDWPHQWV xPRX-100 (aceclidine  and tropicamide 
) Ophthalmic Solution 
x  Aceclidine Ophthalmic Solution
xVehicle Ophthalmic Solution (for PRX-100)
(YDOXDWLRQ&ULWHULD
(IILFDF\0HDVXUHV 3ULPDU\(IILFDF\9DULDEOH
xPercentage of subjects who achieve a 3-line (15-
letters) or greater improvement from pre- treatment in 
the measurement of monocular best-corrected 
distance VA at 45 cm at 1h post-treatment in the 
study eye.
6HFRQGDU\(IILFDF\9DULDEOH
xThe percentage of subjects who achieve 
a 1-line (5-
letter) to 3-line (15- letters) or greater improvement 
from pre-treatment by 1-letter increments in the 
measurement of monocular best- corrected distance 
VA at 45 cm in the study eye at each time point
o0.5, 1, 3, 4, 5 and 7h post-treatment
xPercentage of subjects with at least a 3-line (15-
letter) improvement in the study eye in the 
measurement of post-treatment monocular best-
corrected distance VA at compared to pre-
treatment monocular best- corrected distance VA  
 
xMean monocular best-corr
ected distance logMAR 
VA at near distances in the study eye
oPost- treatment assessments compared to 
pre-treatment assessment
oTwo near testing distances will be 
assessed: 45 cm (all post- treatment time 
points [0.5, 1, 3, 4, 5 and 7h]) and 
xPercentage of subjects with at least a 3-line (15-
letter) improvement in the measurement of post-
treatment binocular best-corrected distance VA at 45 

03Jul2018 CONFIDENTIAL Page  of 
    cm compared to pre-treatment binocular best-
corrected distance VA at 45 cm
o0.5, 1, 3, 4, 5 and 7h post-treatment
xPercentage of subjects with at least a 3-line (15-
letter) improvement in the measurement of post-
treatment binocular best- corrected distance VA  
compared to pre-treatment binocular best-
corrected distance VA 
 
xMean binocular best
-corrected distance logMAR VA
at near distance
oPost- treatment assessments compared to 
pre-treatment assessment
oTwo near testing distances will be 
assessed: 45 cm (all post- treatment time 
points [0.5, 1, 3, 4, 5 and 7h]) and  
([SORUDWRU\ (IILFDF\9DULDEOHV
x
 
 
 
 
 
 
 
 

03Jul2018 CONFIDENTIAL Page  of 
    o  
 
 
 
 
 
6DIHW\0HDVXUHV x Best-corrected VA
x Low-luminance best-corrected VA
x Slit lamp biomicroscopy
x Conjunctival redness
x IOP
x Adverse events (AEs) (reported, elicited, and 
observed)
2WKHU0HDVXUHV x Pupillometry
*HQHUDO6WDWLVWLFDO0HWKRGVDQG7\SHVRI$QDO\VHV
*HQHUDO&RQVLGHUDWLRQV
In general, quantitative/continuous data will be summarized using descriptive statistics (n, 
mean, SD, median, min, and max ). Qualitative/categorical data will be summarized using 
frequencies and percentages. Statistical testing, unless otherwise indicated, will be performed 
at a 2 -sided 0.10 significance level.   
The study eye, defined in section 8.3.1, will be used for all monocular analyses.  The fellow 
eye will inherently be included in all binocular analyses.  Both eyes will be displayed and 
analyzed for all ophthalmic safety variables.
Theprimary and monocular secondary efficacy  analyses will be conducted in the modified
intent -to-treat (mITT) population using statistical models which implicitly impute missing 
data.  The mITT population is defined in section 10.2.1.  

03Jul2018 CONFIDENTIAL Page  of 
    xRandom effect measure: subject within se quence, to account for the correlation 
between treatments and periods within a subject. 
xRepeated measures correlation will be es timated with an unstructured variance-
covariance matrix in the GEE model. 
Standard errors and CIs ( 80 and 90 %) will also be presented for each treatment group and the 
difference between treatment groups. Separate models will be built for each distance (with 45 
cm being primary and  being secondary) and time points. Pairwise comparisons among treatment groups will also be made at each distance and time point using McNemarâ€™s tests. 
6HFRQGDU\(IILFDF\$QDO\VLV
For the secondary efficacy variable of monocular assessment o f best- corrected distance VA, 
the percentage of subjects who achieve a 1 -line (5-letter) to 3-line (15-letters) or greater 
improvement from pre -treatment by 1- letter increments in the measurement of monocular 
best-corrected distance VA will be evaluated at 45 cm for each time point (0.5, 1, 3, 4, 5 and 
7h post -treatment) using the mITT population.  Analyses will be repeated using the ITT 
population.
In addition, will be compared to pre-treatment 
assessments in the study eye.
Descriptive statistics will be presented for each time point and distance as well as for the 
change from pre -dose at each time point and distance by treatment group. The same logistic 
regression models developed for the primary analyses will be used to test these secondary 
endpoints.  
For continuous secondary endpoints, similar mi xed effect models will be employed.  Two-
sided one -sample t-tests from a mixed effects linear model with binocular best-corrected 
distance VA at near distance change from pre- dose as the response variable; sequence, period, 
and treatment as fixed effects ; and subject within sequence as a random effect term with a 
variance component covariance matrix to account for the correlation among measures within 
a subject using Î±= 0.1. Two-sided 80% and 90 % CI will be provided as additional descriptors 
of the data. Separate models will be constructed for each distance and time point separately. 
Pairwise comparisons between treatment groups will also be made at each distanc e and time 
point using one -sample t-tests.
([SORUDWRU\( IILFDF\$QDO\VLV
Exploratory efficacy endpoints will be analyzed  for all available data similarly to the primary 
and secondary endpoints in the mITT population and in the ITT population for sensitivity. All 
exploratory variables will include percentage based and mean based analyses, similar to the primary and secondary endpoints. Pairwise treatment comparisons will be calculated where possible, along with changes from pre
-treatment; otherwise, analy ses will be limited to within 
treatment statistics. 
2WKHU$QDO\VLV
Pupil diameter will be analyzed using similar statistical methods to that of the secondary 
efficacy variable best-corrected distance VA at near distance for each time point separately.  

03Jul2018 CONFIDENTIAL Page  of 
    TABLE OF CONTENTS 
6<1236,6   
/LVWRI$EEUHYLDWLRQV   
 ,1752'8&7,21   
 678'<2%-(&7,9(6  
 &/,1,&$/+<327+(6(6   
 29(5$//678'<'(6,*1   
 678'<3238/$7,21  
 1XPEHURI6XEMHFWVDSSUR[LPDWH  
 6WXG\3RSXODWLRQ&KDUDFWHULVWLFV  
 ,QFOXVLRQ&ULWHULD   
 ([FOXVLRQ&ULWHULD  
 :LWKGUDZDO&ULWHULDLIDSSOLFDEOH   
 678'<3$5$0(7(56  
 (IILFDF\0HDVXUHV   
6.1.1  Primary Efficacy Variable ................................................................24  
6.1.2  Secondary Efficacy Variable ............................................................24  
6.1.3  Exploratory Efficacy Variables: .......................................................25  
6.1.4  Criteria for Effectiveness ..................................................................26  
 6DIHW\0HDVXUHV   
 2WKHU0HDVXUHV   
 678'<0$7(5,$/6  
 6WXG\7UHDWPHQWV  
7.1.1  Study Treatment(s)/ Formulation(s) .................................................26  
7.1.2  Instructions for Use and Administration ...........................................27  
 2WKHU6WXG\6XSSOLHV   
 678'<0(7+2'6$1'352&('85(6   
 6XEMHFW(QWU\3URFHGXUHV   
8.1.1  Overview ...........................................................................................28  
8.1.2  Informed Consent..............................................................................28  
8.1.3  Washout Intervals .............................................................................28  
8.1.4  Procedures for Final Study Entry ......................................................29  
8.1.5  Pregnancy ..........................................................................................29  
8.1.6  Methods for Assignment to Treatment Groups: ...............................29  
 &RQFXUUHQW7KHUDSLHV   
8.2.1  Prohibited Medications/Treatments ..................................................30  
8.2.2  Escape Medications ..........................................................................30  
8.2.3  Special Diet or Activities ..................................................................30  
 ([DPLQDWLRQ3URFHGXUHV  
8.3.1  Procedures to be performed at the Study Visit with Regard to Study 
Objective(s) ....................................................................................................30  
 6FKHGXOHRI9LVLWV0HDVXUHPHQWVDQG'RVLQJ  
03Jul2018 CONFIDENTIAL Page  of 
    8.4.1  Scheduled Visit .................................................................................34  
8.4.2  Unscheduled Visits ...........................................................................34  
 &RPSOLDQFHZLWK3URWRFRO   
 6XEMHFW'LVSRVLWLRQ   
8.6.1  Completed Subjects ..........................................................................34  
8.6.2  Withdrawn Subjects ..........................................................................34  
8.6.3  Discontinued Subjects .......................................................................35  
 6WXG\7HUPLQDWLRQ   
7KHVWXG\PD\EHWHUPLQDWHG DWDQ\WLPHE\WKH,QYHVWLJDWRUWK HVSRQVRU
DQGRU2UDZLWKDSSURSULDWHQRWLILFDWLRQ   
 6WXG\'XUDWLRQ   
 0RQLWRULQJDQG4XDOLW\$VVXUDQFH   
 $'9(56((9(176   
 $GYHUVH(YHQW   
9.1.1  Severity .............................................................................................36  
9.1.2  Relationship to Investigational Product ............................................36  
9.1.3  Expectedness .....................................................................................37  
 6HULRXV$GYHUVH(YHQWV   
 3URFHGXUHVIRU5HSRUWLQJ$GYHUVH(YHQWV   
9.3.1  Reporting a Suspected Unexpected Adverse Reaction .....................39  
9.3.2  Reporting a Serious Adverse Event ..................................................39  
 3URFHGXUHVIRU8QPDVNLQJLIDSSOLFDEOH   
 7\SHDQG'XUDWLRQRIWKH)ROORZXSRI6XEMHFWVDIWHU$GYHUVH(Y HQWV  
 67$7,67,&$/+<327+(6(6$1'0(7+2'62)$1$/<6(6  
  *HQHUDO&RQVLGHUDWLRQV  
  6WXG\3RSXODWLRQV   
10.2.1  Modified Intent-to-Treat Population .................................................41  
10.2.2  Intent-to-Treat Population .................................................................42  
10.2.3  Modified Per Protocol Population ....................................................42
10.2.4  Per Protocol Population ....................................................................42  
10.2.5  Safety Population ..............................................................................42  
  *HQHUDO,PSXWDWLRQ0HWKRGV   
  3ULPDU\(IILFDF\9DULDEOH  
  6HFRQGDU\(IILFDF\9DULDEOHV  
  ([SORUDWRU\(IILFDF\9DULDEOHV   
  2WKHU0HDVXUHV   
  6DPSOH6L]H   
  'HPRJUDSKLFDQG%DVHOLQH&KDUDFWHULVWLFV   
  3ULPDU\(IILFDF\$QDO\VHV  
  6HFRQGDU\(IILFDF\$QDO\VLV   
  ([SORUDWRU\(IILFDF\$QDO\VLV   
  2WKHU0HDVXUHV   
  $GMXVWPHQWIRU0XOWLSOLFLW\   
  6DIHW\$QDO\VLV  
03Jul2018 CONFIDENTIAL Page  of 
     &203/,$1&(:,7+*22'&/,1,&$/35$&7,&(6(7+,&$/
&216,'(5$7,216$1'$'0,1,675$7,9(,668(6   
  3URWHFWLRQRI+XPDQ6XEMHFWV   
11.1.1  Subject Informed Consent.................................................................47  
11.1.2  IRB Approval ....................................................................................48  
  (WKLFDO&RQGXFWRIWKH6WXG\   
  6XEMHFW&RQILGHQWLDOLW\   
  'RFXPHQWDWLRQ  
11.4.1  Retention of Documentation .............................................................49  
  /DEHOLQJ3DFNDJLQJ6WRUDJH$FFRXQWDELOLW\DQG5HWXUQRU 'LVSRVDORI
,QYHVWLJDWLRQDO3URGXFW   
11.5.1  Labeling/Packaging...........................................................................49  
11.5.2  Storage of Investigational Product ....................................................50  
11.5.3  Accountability of Investigational Product ........................................50  
11.5.4  Return or Disposal of Investigational Product ..................................50  
  5HFRUGLQJRI'DWDRQ6RX UFH'RFXPHQWVDQG( OHFWURQLF&DVH5HSRU WV
)RUPVH&5)V  
  +DQGOLQJRI%LRORJLFDO6SHFLPHQV   
  3XEOLFDWLRQV   
 5()(5(1&(6   
$SSHQGL[ 6FKHGXOHRI9LV LWVDQG0HDVXUHPHQWV   
$SSHQGL[ ([DPLQDWLRQ3URFHGXUHV 7HVWV(TXLSPHQWDQG7HFK QLTXHV  
$SSHQGL[ +DQGOLQJRI%LRORJLFDO6SHFLPHQV   
$SSHQGL[ 3URWRFRO$PHQGPHQW6XPPDU\   
*HQHUDO&RQVLGHUDWLRQV  
o 6WXG\3RSXODWLRQV   
0RGLILHG,QWHQWWR7UHDW3RSXODWLRQ ...............................................81  
Intent-to-Treat Population ..............................................................................82  
Modified Per Protocol Population ..................................................................83  
o *HQHUDO,PSXWDWLRQ0HWKRGV  
o 3ULPDU\(IILFDF\9DULDEOH   
o 6HFRQGDU\(IILFDF\9DULDEOHV  
o 6DPSOH6L]H   
o 3ULPDU\(IILFDF\$QDO\VHV   
   
[â€¦] 6.1.2 Secondary Efficacy Variable .........................................................98  
 ([SORUDWRU\(IILFDF\9DULDEOHV  .....................................................100  
6.1.4 Criteria for Effectiveness .....................................................................101  
*HQHUDO&RQVLGHUDWLRQV  
>Â«@6HFRQGDU\(IILFDF\9DULDEOHV   
2WKHU0HDVXUHV   
>Â«@6HFRQGDU\(IILFDF\$QDO\VLV  
2WKHU0HDVXUHV   
*HQHUDO&RQVLGHUDWLRQV  
03Jul2018 CONFIDENTIAL Page  of 
    >Â«@6HFRQGDU\(IILFDF\9DULDEOHV   
([SORUDWRU\(IILFDF\9DULDEOHV  
2WKHU0HDVXUHV   
>Â«@6HFRQGDU\(IILFDF\$QDO\VLV  
([SORUDWRU\(IILFDF\$QDO\VLV   
2WKHU0HDVXUHV   
$SSHQGL[ 6SRQVRUDQG2UD$SSURYDOV  
$SSHQGL[ ,QYHVWLJDWRUÂ¶V6LJQDWXUH  
/LVW RI $EEUHYLDWLRQV
ADHD Attention-Deficit/Hyperactivity Disorder
AE adverse event
cd/m2candela per square meter
CFR Code of Federal Regulations
CI confidence interval
CST Clinical Trial Suite
eCRF electronic case report form
D diopter
EKG electrocardiogram
ETDRS Early Treatment of Diab etic Retinopathy Study
FDA Food and Drug Administration
GCP Good Clinical Practice
GEE Generalized Estimating Equation
ICF informed consent form
IEC independent ethics committee
IND investigational new drug application
IOL intraocular lens
IOP intraocular pressure
IP investigational product
IRB institutional/independent review board
ITT intent to treat
LASEK laser-assisted sub-epithelial keratectomy
LASIK laser in situ keratomileusis
LOCF last observation carried forward
logMAR logarithm of the minimum angle of resolution
MAX maximum
MedDRA Medical Dictionary for Regulatory Activities
MIN minimum
mmHg millimeters of mercury
 

03Jul2018 CONFIDENTIAL Page  of 
    NCS not clinically significant
OD right eye
OS left eye
OU both eyes
OTC over the counter
PP per protocol
PRK photorefractive keratectomy
QD once daily
RGP rigid gas permeable
SAE serious adverse event
SAP statistical analysis plan
SD standard deviation
SOP standard operating procedure
VA visual acuity
,1752'8&7,21
Presbyopia is defined by a loss in the ability of the eye to adjust its focal length so that objects at 
different distances produce focused images on the retina. As the eye ages, the lens of the eye becomes less able to change shape. Hardening of the lens, along with weakening of the ciliary muscles, plays a major role in the pathogenesis of presbyopia and leads to symptoms such as blurred vision, eye strain and headach e after reading or computer use (Truscott 2009; Helmholtz
1855; Ostrin and Glasser 2007; Scarcelli 2011).  
Presbyopia affects most people over 45 years of ag e and continues to worsen until approximately 
65 years of age. Based on data from 228 countries, it was estimated that in 2005, presbyopia 
affected more than 1 billion people worldwide. Pr esbyopia is projected to increase to 1.78 billion 
people by 2050.  More than half of the people wi th this condition do not have adequate treatment 
options, which results in some level of disability when performing tasks that require near visual 
acuity ( Holden 2008).  
Current treatments available for presbyopia include the use of reading glasses, contact lenses, or 
refractive (including laser) or intraocular lens (IOL) surgery. Pharmaceutical therapies have been explored but, thus far, continue to be limited in treating presbyopia without being associated with undesirable adverse effects ( Gilmartin 1995 ).  
PRX-100 is an ophthalmic solution that contains a low dose of aceclidine  and tropicamide . Both aceclidine and tropicamide  have been used extensively in humans for 
ophthalmic indications. Aceclidine is a parasympat homimetic miotic agent that is approved for 
lowering IOP in Europe. In 1969, a 2% solution of aceclidine was approved in several European countries for the treatment of glaucoma. Furthermore, aceclidine has been used at concentrations of up to 4% in humans. Tropicamide is an anticholinergic drug that was approved for human use in the US in 1960. Tropicamide induces mydriasis (pupil dilation) and cycloplegia (paralysis of the ciliary muscle) and is used to facilitate ophthalmic patient examinations. Tropicamide is 

03Jul2018 CONFIDENTIAL Page  of 
    b.bladder medication (eg UrecholineÂ®, bethanechol) 
c.antipsychotics 
d.antidepressants 
e.attention â€“deficit/hyperactivity disorder (ADHD) medications 
f.alpha-blockers (eg, tamsulosin, FlomaxÂ®, JaylnÂ®, UroxatralÂ®, RapafloÂ®) 
g.anticholinergics (eg, atropine, belladonna, benztropine, dicyclomine, donepezil, 
hyoscyamine, propantheline, scopolamine, trihexphenidyl) 
h.muscarinic receptor agonists or cholinergic agonists (eg, SalagenÂ®, EvoxacÂ®)
i.over-the-counter (OTC) or prescription antihistamines or decongestants 
j.any prescribed topical ophthalmic medications 
k.recreational drug use (eg, marijua na, methadone, heroin, cocaine); 
20.Have a diagnosis of diabetes mellitus or a history of elevated blood sugar; 
21.Have a condition or a situation, which in the Investigatorâ€™s opinion, may put the 
subject at increased risk, confound study data, or interfere significantly with the subjectâ€™s study participation, including but  not limited to unstable: cardiovascular, 
hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.  
5.5
:LWKGUDZDO &ULWHULD LI DSSOLFDEOH
Subjects will be withdrawn from the study if any of the following criteria are met: 
1. Be a female of childbearing potential who is currently pregnant, nursing or 
planning a pregnancy; tests positive to a urine pregnancy test at visit 2, 3 
or 4; or refuses to use an ade quate method of contraception for the 
duration of the study; 
2. Have an active ocular infection at visit 2, 3 or 4 (bacterial, viral or fungal), 
positive history of an ocular herpetic infection, preauricular
lymphadenopathy, or ongoing, active ocular inflammation (eg, moderate to severe blepharitis, allergic conjunctiv itis, peripheral ulce rative keratitis, 
scleritis, uveitis) in either eye.  
Subjects may also be withdrawn from the study for the following reasons: 
xAE
xLost to follow-up 
xWithdrawal of consent by subject 
xInvestigator discretion 
xDeath 
xSubject not following required study procedures 
03Jul2018 CONFIDENTIAL Page  of 
    xStudy terminated by the Sponsor 
xOther 
Subject withdrawals will be documented clearly on the subjectâ€™s source 
document.   
678'<3$5$0(7(56
6.1(IILFDF\ 0HDVXUHV
6.1.1 Primary Efficacy Variable 
xPercentage of subjects who achieve a 3-line (15-letters) or greater 
improvement from pre-treatment in the measurement of monocular best-
corrected distance VA at 45 cm at 1h post-treatment in the study eye. 
6.1.2 Secondary Efficacy Variable 
xThe percentage of subjects who achiev e a 1-line (5-letter) to 3-line (15-
letters) or greater improvement from pre-treatment by 1-letter increments in the measurement of m onocular best-corrected distance VA 
will be evaluated at 45 cm for each time point 
o0.5, 1, 3, 4, 5 and 7h post-treatment 
xPercentage of subjects with at least a 3-line (15-letter) improvement in 
the study eye in the measurement of post-treatment monocular best-
corrected distance VA at  compared to pre-treatment monocular 
best-corrected distance VA at  
 
xMean monocular best-corrected distance logMAR VA at near distances 
in the study eye 
oPost-treatment assessments compared to pre-treatment 
assessment 
oTwo near testing distances will be assessed: 45 cm (all post-
treatment time points [0.5, 1, 3, 4, 5 and 7h]) and  
  
xPercentage of subjects with at least a 3-line (15-letter) improvement in the measurement of post-treatment binoc ular best-corrected distance VA 
at  compared to pre-treatment binocular best-corrected distance 
VA at 

03Jul2018 CONFIDENTIAL Page  of 
    o  
xPercentage of subjects with at least a 3-line (15-letter) improvement in 
the measurement of post-treatment binocular best-corrected distance VA 
at  compared to pre-treatment  binocular best-corrected distance 
VA at  
  
xMean binocular best-corrected dist ance logMAR VA at near distance 
oPost-treatment assessments compared to pre-treatment assessment 
oTwo near testing distances will be assessed: 45 cm (all post-treatment time points [0.5, 1, 3, 4, 5 and 7h]) and  
 
6.1.3 Exploratory Efficacy Variables: 
x  
 
   
 
 
  
  
 
 
  
 
 
 
 
 
 
 

03Jul2018 CONFIDENTIAL Page  of 
    o  
 
 
  
 
 
 
  
 
6.1.4 Criteria for Effectiveness 
Changes in best-corrected distance VA at  near distance will be calculated as 
the difference, in logMAR units, between the post-treatment monocular (study 
eye) and binocular best-corrected distance VA measurements at near (45 cmand  minus the pre-treatment monocular (study eye) and binocular best-corrected distance VA measurements at near (45 cm and   A 3-line improvement in VA is considered clinically meaningful. 
6.2
6DIHW\ 0HDVXUHV
xUrine pregnancy test  
xBest-corrected distance VA 
xLow-luminance best-corrected distance VA 
xSlit-lamp biomicroscopy 
xConjunctival redness 
xIOP 
xAEs (reported, elicited, and observed)  
6.32WKHU 0HDVXUHV
xPupillometry 
678'<0$7(5,$/6
7.16WXG\ 7UHDWPHQWV
7.1.1 Study Treatment(s)/ Formulation(s) 
The study treatments are as follows: 

03Jul2018 CONFIDENTIAL Page  of 
    â€¢Muscarinic receptor agonists or cholinergic agonists (eg, SalagenÂ®,
EvoxacÂ®): 2 weeks
â€¢Over-the-counter and prescription antihistamines or decongestants: 2 
weeks
â€¢Artificial tears: on the day of or during visit 1, 2, 3 or 4  
â€¢Any prescribed topical ophthalmic medications: 2 weeks 
8.1.4 Procedures for Final Study Entry 
Subjects must satisfy all inclusion a nd none of the exclusion criteria in order 
to be entered into the study. 
8.1.5 Pregnancy 
Females must have a negative urine pr egnancy test at visit 1, if female of 
childbearing potential (those who have experienced menarche and who are not surgically sterilized [bilateral tubal ligation, hysterectomy or bilateral oophorectomy] or post-menopausal [12 mont hs after last menses]) and must 
use adequate birth control throughout the study period. Adequate birth control is defined as hormonal â€“ oral, implantable, injectable, or transdermal 
contraceptives; mechanical â€“ spermicide in conjunction with a barrier such as 
condom or diaphragm; intrauterine device (IUD); or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control. 
In the event a female has a positive urine pregnancy test at visit 2, 3 or 4, the 
subject will be withdrawn from the study and the Investigator will notify Ora 
and the sponsor within 24 hours of knowledge of the event. 
8.1.6 Methods for Assignment to Treatment Groups: 
Each subject who signs an informed consent form will be assigned a screening 
number.  Screening numbers will be assigned in sequential order beginning with 001.  Once a subject meets all qualification criteria, he/she will be randomized in a 1:1:1 ratio to one of three Latin square design sequences 
[(1,2,3), (2,3,1), and (3,1,2)] detailing the order in which treatments (1: PRX-
100, 2: aceclidine, 3: vehicle) will be ad ministered over the three study visits 
and will be assigned a 4-digit subj ect number.  Subject numbers will be 
assigned in a sequential order starting at the lowest number available.  No 
numbers will be skipped or omitted. Randomization will be used to avoid bias 
in the assignment of subjects to treatment, to increase the likelihood that 
known and unknown subject attributes (e.g., demographics and baseline characteristics) are evenly balanced across treatment groups, and to enhance 
the validity of statistical comparisons across treatment groups.  Masked treatment will be used to reduce potenti al of bias during data collection and 
evaluation of clinical endpoints.  
03Jul2018 CONFIDENTIAL Page  of 
    xInformed consent and HIPAA 
xDemographics 
xMedical/medication history 
xUrine pregnancy test (for females of child-bearing potential) 
xInclusion/exclusion criteria review 
xScreening assessments:  
oScreening monocular best-corrected distance visual acuity (VA) at 45 cm* 
oScreening monocular best-corrected distance VA* 
xSlit-lamp biomicroscopy 
xFluorescein staining 
oSubjects should wait at least 30 minutes with his/her eyes closed following 
fluorescein staining  
 
 
  
 
 
  
 
 
 
9LVLWV'D\VÂ“Â“Â“
xMedical and medication history update  
xUrine pregnancy test (for females of child-bearing potential) 
xSubjects will be asked to read printed instructions about what will be completed at 
each visit prior to beginning baseline/pre-treatment assessments. 
xBaseline/pre-treatment assessments:  
oPupillometry   
oMonocular best-corrected distance VA at  
oBinocular best-corrected distance VA at  
oMonocular best-corrected distance visual acuity at * 
oBinocular best-corrected distance VA at  

03Jul2018 CONFIDENTIAL Page  of 
    oMonocular best-corrected distance VA* 
oBinocular best-corrected distance VA* 
oMonocular low-luminance be st-corrected distance VA* 
oBinocular low-luminance best-corrected distance VA* 
o  
  
  
  
  
 
  
oSlit-lamp biomicroscopy
oConjunctival redness assessment 
xRandomization will occur at visit 2 for all qualified subjects. All randomized 
subjects will receive each treatment once at each visit 2, 3 and 4 (crossover study 
design). Subjects randomization will dictate which treatment will be administered at each study visit. 
7UHDWPHQW$GPLQLVWUDWLRQ
xInstillation of PRX-100, aceclidine, or vehicle OU 
o  
 
 
 
3RVWWUHDWPHQWDVVHVVPHQWV

oAE query post-treatment and 1 hour post-treatment 
oThe following assessments will be made 0.5, 1, 3, 4, 5 and 7 hours post-treatment:  
ÂƒConjunctival redness assessment 
ÂƒPupillometry   
ÂƒMonocular best-corrected distance VA at  
ÂƒBinocular best-corrected distance VA at  
ÂƒMonocular best-corr ected distance VA*

03Jul2018 CONFIDENTIAL Page  of 
    ÂƒBinocular best-corrected distance VA* 
ÂƒMonocular low-luminance be st-corrected distance VA* 
ÂƒBinocular low-luminance best-corrected distance VA* 
oThe following assessments will be made 1, 4 and 5 hours post-treatment:  
ÂƒMonocular best-corrected distance VA at  
ÂƒBinocular best-corrected distance VA at  
ÂƒAll best-corrected distance VA at  assessments to be assessed 
immediately following best-corrected distance VA at 45 cm 
assessments 
oThe following assessments will be made 1 and 5 hours post-treatment 
following binocular low-luminance best-corrected distance VA:
Âƒ  
  
  
  
  
 
 
oFollowing the 7-
hours post-treatment assessments: 
ÂƒSlit lamp biomicroscopy 
ÂƒIOP 
ÂƒAE query 
$VVHVVPHQWIRU6WXG\([LW
xSubjects will be assessed for study exit. Study exit can occur at either visit 1, 2, 3, 
or 4. If a subject completes the study, Study exit will occur at Visit 4. 
* VA to be assessed with best distance correction  
  
** Best effort will be made to adhere to  assessment time points. No 
minimum/maximum windows are defined for any post-treatment assessment time point. 

03Jul2018 CONFIDENTIAL Page  of 
    8.46FKHGXOH RI 9LVLWV 0HDVXUHPHQWV DQG 'RVLQJ
8.4.1 Scheduled Visit 
Refer to Appendix 1 for a schedule of measurements at the Visit. 
8.4.2 Unscheduled Visits 
In the case of an AE, an Unscheduled Visit may be performed by the 
Investigator. Unscheduled Visit assessments can include any of the following: 
ÂƒMedical/medication history 
ÂƒUrine pregnancy test 
ÂƒVA assessments 
ÂƒSlit-lamp biomicroscopy 
ÂƒConjunctival redness 
ÂƒIOP 
ÂƒFluorescein staining 
ÂƒAE query 
The Investigator may perform additional assessments, if needed. All additional assessments will be documented in the subjectâ€™s source  document. 
8.5
&RPSOLDQFH ZLWK 3URWRFRO
This study will be conducted in complian ce with the protocol, the ethical principles 
that have their origin in the Declaration of Helsinki, the International Conference on 
Harmonisation (ICH) consolidated Guideline E6 for Good Clinical Practice (GCP) 
(CPMP/ICH/135/95), and applicable regulatory requirement(s), such as Food and Drug Administration (FDA) GCP Regulations and Code of Federal Regulations Title 21, parts 11, 50, 54, 56 and 312, as appropriate. 
8.6
6XEMHFW 'LVSRVLWLRQ
8.6.1 Completed Subjects 
A completed subject is one who has not been discontinued from the study. 
8.6.2 Withdrawn Subjects 
A subject may be withdrawn for meeting any of the withdrawal criteria as 
described in Section 5.5.  
03Jul2018 CONFIDENTIAL Page  of 
    8.6.3 Discontinued Subjects 
A discontinued subject is one who does not  complete the four (4) protocol defined 
study visits. A subject MAY be discontinued at the discretion of the Investigator, 
Sponsor, and/or the IRB/IEC. Subjects will also be discontinued if the following 
criteria is met:
x  
Prior to discontinuing a subject, every effort should be made to obtain as much 
follow-up data as possible, and to retrieve all study materials.  Adverse events 
(AEs) will be followed as described in Section 9.
8.76WXG\ 7HUPLQDWLRQ
7KH VWXG\ PD\ EH WHUPLQDWHG DW DQ\ WLPH E\ WKH ,QYHVWLJDWRU WK H
VSRQVRU DQGRU 2UD ZLWK DSSURSULDWH QRWLILFDWLRQ
8.86WXG\'XUDWLRQ
This study is comprised of 4 visits over a total duration of approximately 7 weeks. 
8.90RQLWRULQJ DQG 4XDOLW\ $VVXUDQFH
During the course of the study an Ora, Inc. monitor, or designee, will make routine 
site visits to review protocol compliance,  assess study drug accountability, and ensure 
the study is being conducted according to the pertinent regulatory requirements. The 
review of the subjectsâ€™ medical records will be performed in a manner that adequately maintains subject confidentiality. Further details of the study monitoring will be outlined in a monitoring plan. 
Regulatory authorities of domestic and foreig n agencies, Ora, Inc. quality assurance 
and/or its designees may carry out on-site inspections and/or audits which may 
include source data checks. Therefore, direct access to the original source data will be required for inspections and/or audits. All in spections and audits will be carried out 
giving consideration to data protection as we ll as subject confidentiality to the extent 
that local, state, and federal laws apply. 
$'9(56((9(176
9.1$GYHUVH (YHQW
An AE is defined as any untoward medical occurrence associated with the use of an investigational product (IP) in humans, whether or not considered IP-related. An AE 

03Jul2018 CONFIDENTIAL Page  of 
    can be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of an investigational product, 
without any judgment about causality. An AE can arise from any use of the investigational product (e.g., off-label use, use in combination with another drug or medical device) and from any route of admi nistration, formulation, or dose, including 
an overdose. An AE can arise from any delivery, implantation, or use of a medical device, including medical device failure, patient characteristics that may impact medical device performance (e.g., anatomica l limitations), and therapeutic parameters 
(e.g., energy applied, sizing, dose releas e) associated with a medical device. 
All AEs spontaneously reported by the subject and/or in response to an open question from study personnel or revealed by observation, physical examination or other diagnostic procedures will be recorded in the subjectâ€™s source document and eCRF. 
Any clinically relevant deterioration in clinical finding is considered an AE and must 
be recorded. When possible, signs and symptoms indicating a common underlying 
pathology should be noted as one comprehensive event. 
Documentation regarding the AE should be mad e as to the nature, date of onset, end 
date, severity, relationship to investigati onal product, expectedness, action(s) taken, 
seriousness, and outcome of any sign or symptom observed by the physician or 
reported by the patient upon indirect questioning. 
All AEs will be collected from the time a subject signs the informed consent form 
through the subjectâ€™s study exit visit. 
9.1.1 Severity 
Severity of an AE is defined as a qualitative assessment of the degree of 
intensity of an AE as determined by the Investigator or reported to him/her by the patient/subject.  The assessment of severity is made irrespective of 
relationship to investigational product or seriousness of the event and should be evaluated according to the following scale: 
xMild : Event is noticeable to the subject, but is easily tolerated and does 
not interfere with the subjectâ€™s daily activities.
xModerate :  Event is bothersome, possibly requiring additional therapy, 
and may interfere with the subjectâ€™s daily activities.
xSevere :  Event is intolerable, necessitates additional therapy or alteration 
of therapy, and interferes with the subjectâ€™s daily activities.
9.1.2 Relationship to Investigational Product 
The relationship of each AE to the investigational product should be 
determined by the Investigator using these explanations: 
03Jul2018 CONFIDENTIAL Page  of 
    xSuspected :  A reasonable possibility exists that the investigational product 
caused the AE.
xNot Suspected: A reasonable possibility does not exist that the 
investigational product caused the AE. 
Suspected adverse reaction means any AE for which there is a reasonable 
possibility that the investigational product caused the AE .  â€œReasonable 
possibilityâ€ means there is evidence to suggest a causal relationship between the investigational product and the AE.  Types of evidence that would suggest a causal relationship between the investigational product and the AE include:  a single occurrence of an event that is uncommon and known to be strongly associated with investigational product exposure (e.g., angioedema, hepatic injury, Stevens-Johnson Syndrome); one or more occurrences of an event that 
is not commonly associated with investigational product exposure, but is 
otherwise uncommon in the population exposed to the investigational product (e.g., tendon rupture); an aggregate analysis of specific events observed in a clinical trial (such as known consequences of the underlying disease or condition under investigation or other events that commonly occur in the study population independent of drug therapy) that indicates those events occur more frequently in the investig ational product-treatment group than in a 
concurrent or historical control group. 
9.1.3 Expectedness 
The expectedness of an AE should be determined based upon existing safety 
information about the investigational product using these explanations: 
xUnexpected:  an AE that is not listed in the Investigatorâ€™s Brochure (IB) or 
is not listed at the specificity or severity that has been observed. 
xExpected :  an AE that is listed in the IB at the specificity and severity that 
has been observed. 
xNot applicable:  an AE unrelated to the investigational product. 
Adverse events that are mentioned in the IB as occurring with a class of 
products or as anticipated from the pharmacological (or other) properties of the product, but are not specifically mentioned as occurring with the particular product under investigation are to be considered unexpected. 
The Investigator should initially classify the expectedness of an AE, but the 
final classification is subject to the Medical Monitorâ€™s determination.
03Jul2018 CONFIDENTIAL Page  of 
    9.26HULRXV $GYHUVH (YHQWV
An AE is considered serious if, in the view of either the Investigator or sponsor, it 
results in any of the following outcomes: 
xDeath; 
xA life-threatening AE; 
oNote:  An AE is considered â€œlife -threateningâ€ if, in the view of either the 
Investigator or sponsor, its occurrence places the patient or subject at 
immediate risk of death.  It does not include an AE that, had it occurred in a more severe form, might have caused death. 
xInpatient hospitalization or prolongation of existing hospitalization; 
oNote:  The term â€œinpatient hospitalizationâ€ refers to any inpatient admission 
(even if less than 24 hours).  For chronic or long-term inpatients, inpatient admission includes transfer within the hospital to an acute/intensive care inpatient unit.  Inpatient hospitalization does not include:  emergency room visits; outpatient/same-day/ambulatory procedures; observation/short stay units; rehabilitation facilities; hospice facilities; nursing homes; or clinical research/phase 1 units. 
oNote:  The term â€œprolongation of existing hospitalizationâ€ refers to any extension of an inpatient hospitalization beyond the stay anticipated or required for the reason for the initial admission as determined by the Investigator or treating physician. 
xA persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions; 
oNote:  A serious adverse event (SAE) specifically related to visual threat 
would be interpreted as any potential impairment or damage to the subjectâ€™s eyes (e.g., hemorrhage, retinal detachment, central corneal ulcer or damage to the optic nerve). 
xA congenital anomaly/birth defect. 
Important medical events that may not result in death, are life-threatening, or require hospitalization may be considered seri ous when, based upon appropriate medical 
judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. 
03Jul2018 CONFIDENTIAL Page  of 
    9.33URFHGXUHV IRU 5HSRUWLQJ $GYHUVH (YHQWV
All AEs and their outcomes must be reported to Ora, the study sponsor, and the 
IRB/IEC as required by the IRB/IEC, federal, state, or local regulations and governing health authorities and recorded on the appropriate subject source document and eCRF. 
9.3.1 Reporting a Suspected Unexpected Adverse Reaction 
All AEs that are â€˜suspectedâ€™ and â€˜unexpectedâ€™ are to be repor ted to Ora, the 
study sponsor and the IRB/IEC as required by the IRB/IEC, federal, state, or 
local regulations and governing health authorities. 
9.3.2 Reporting a Serious Adverse Event 
To ensure subject safety, all SAEs, regardless of relationship to the investigational product, must be immediately reported by the Investigator to Ora and the sponsor within 24 hours of becoming aware of the event.  All information relevant to the SAE must be recorded on the appropriate source document, SAE Report Form and eCRF.  The Investigator is obligated to pursue and obtain information requested by Ora and/or the sponsor in addition to the information reported on the source document, SAE Report Form and eCRF.  All subjects experiencing a SAE must be followed up and the outcome reported. 
In the event of a SAE, the Investigator must notify Ora and the sponsor 
immediately; obtain and maintain in his/her files all pertinent medical records, information, and medical judgments from colleagues who assisted in the 
treatment and follow-up of the subject; provide Ora and the study sponsor 
with a complete case history, which includes a statement as to whether the event was or was not suspected to be related to the use of the investigational product; and inform the IRB of the AE within their guidelines for reporting SAEs. 
Contact information for reporting SAEs: 

03Jul2018 CONFIDENTIAL Page  of 
    9.43URFHGXUHV IRU 8QPDVNLQJ LI DSSOLFDEOH
When medically necessary, the Investigator may need to determine what treatment 
has been assigned to a subject.  When possible (i.e., in non-emergent situations), Ora and/or the study sponsor should be notified before unmasking investigational product. A two-panel clinical label with scratch offs will be used for unmasking.  
9.5
7\SH DQG 'XUDWLRQ RI WKH )ROORZXS RI 6XEMHFWV DIWHU $GYHUVH
(YHQWV
The Investigator will follow unresolved AEs to resolution, until the subject is lost to 
follow-up or until the AE is otherwise explained.  Resolution means the subject has returned to baseline state of health or the Investigator does not expect any further improvement or worsening of the AE.  If the subject is lost to follow-up, the Investigator should make 3 reasonable attempts to contact the subject via telephone, post, or certified mail.  All follow- up will be documented in the subjectâ€™s source 
document. Non-serious AEs identified on the last scheduled contact must be recorded 
on the source document with the status noted.  
If the Investigator becomes aware of any new information regarding a SAE (i.e. 
resolution, change in condition, or new treatment), a new Serious Adverse Event 
Report Form must be completed and faxed to Ora and/or the study sponsor within 24 
hours.  The original SAE Report Form is not to be altered.  The Report Form should describe whether the event has resolved or continues and how the event was treated. 
 67$7,67,&$/+<327+(6(6$1'0(7+2'62)$1$/<6(6
10.1*HQHUDO &RQVLGHUDWLRQV
All quantitative/continuous study assessments will be summarized by treatment (or treatment sequence) and visit and time poi nt (as applicable) using descriptive 
statistics (n, mean, SD, median, minimum, and maximum.  All qualitative/categorical study assessments will be summarized by treatment (or treatment sequence), visits, and time point (as applicable) using fr equency counts and percentages.   
Statistical testing, unless otherwise indicated, will be performed at a 2-sided 0.10 significance level.  When applicable, two-s ided 80% and 90% CIs will be reported.  
All p-values ( P) will be displayed to four decimal places, with P less than 0.0001 
presented as '< 0.0001' and Pgreater than 0.9999 presented as â€˜> 0.9999â€™.  

03Jul2018 CONFIDENTIAL Page  of 
    xPercentage of subjects with at least a 3-line (15-letter) improvement in the study 
eye in the measurement of post-treatment monocular best-corrected distance VA
 compared to pre-treatment monoc ular best-corrected distance VA  
 
xMean monocular best-corrected distance logMAR VA at near distances in the 
study eye 
oPost-treatment assessments compared to pre-treatment assessment 
oTwo near testing distances will be a ssessed:  (all post-treatment time 
points [0.5, 1, 3, 4, 5 and 7h]) and  
xPercentage of subjects with at least a 3-line (15-letter) improvement in the 
measurement of post-treatment binocular be st-corrected distance VA at 45 cm 
compared to baseline binocular best-corrected distance VA at 45 cm
o0.5, 1, 3, 4, 5 and 7h post-treatment  
xPercentage of subjects with at least a 3-line (15-letter) improvement in the measurement of post-treatment binocular be st-corrected distance VA at  
compared to baseline binocular be st-corrected distance VA at  
  
x Mean binocular best-corrected distance logMAR VA at near 
oPost-treatment assessments compar ed to pre-treatment assessment 
oTwo near testing distances will be assessed:  (all post-treatment time points [0.5, 1, 3, 4, 5 and 7h]) and  
10.6
([SORUDWRU\ (IILFDF\ 9DULDEOHV
The exploratory effi
cacy variables are: 
x
   
  
  
 
  
 
 
 

03Jul2018 CONFIDENTIAL Page  of 
    Descriptive statistics will be presented for  each time point and distance by treatment 
group. Testing of the percentage of subj ects with at least a 3-line (15-letter)
improvement in the study eye from pre-dose will be completed accounting for the 
correlations between treatments and pe riods within a subject using a logistic 
(binomial error and logit link) model estim ated by generalized estimating equation 
methods. Aspects of the model include: 
â€¢Response measure: indicator of whether the subject had at least a 3-line (15-letter) 
improvement in the study eye from pre-dos e in the monocular assessment of best-
corrected distance VA at . â€¢ Fixed effect explanatory measures: sequence, period, and treatment.  â€¢ Random effect measure: subject within sequence, to account for the correlation 
between treatments and periods within a subject. â€¢ Repeated measures correlation will be estimated with an unstructured variance-
covariance matrix.  Standard errors and CIs (80 and 90%) will also be presented for each treatment 
group and the difference between treatment g roups. Separate models will be built for 
each distance (with 45 cm being primary and  being secondary) and time point separately. Pairwise comparisons among tr eatment groups will also be made at each 
distance and time point using McNemarâ€™s tests. 
10.11
6HFRQGDU\ (IILFDF\ $QDO\VLV
Descriptive statistics will be presented for  each time point and distance as well as 
for the change from pre-dose at each time point and distance by treatment group. The same logistic regression models developed for the primary analyses will be used to test secondary proportion endpoints.  F or continuous secondary endpoints, similar 
mixed effect models will be employed.  Two-sided one-sample t -tests from a mixed 
effects linear model with monocular best-corrected distance VA at near from pre-dose as the response variable; sequence, period, and treatment as fixed effect variables; and subject within sequence as a random effect term with a variance component covariance matrix to account for the correlation among measures within a subject using Î± = 0.10 and two-sided 80% and 90% CI will be provided as 
additional descriptors of the data.  Separate models will be built for each distance 
and time point separately. Pairwise comp arisons among treatment groups will also 
be made at each distance and time point using one-sample t-tests.  
10.12
([SORUDWRU\ (IILFDF\ $QDO\VLV
Exploratory efficacy endpoints will be analyzed for all available data similarly to the primary and secondary endpoints in the mITT population and in the ITT population for sensitivity. All exploratory va riables will include percentage based 

03Jul2018 CONFIDENTIAL Page  of 
    enrollment into the study.  If the subject is under the legal age of consent, the 
consent form must be signed by a legal guardian or as required by state and/or 
local laws and regulations. 
All informed consent/assent forms must be approved for use by the sponsor 
and receive approval/favorable opinion from an IRB/IEC prior to their use.  If the consent form requires revision (e.g ., due to a protocol amendment or 
significant new safety information), it is the Investigatorâ€™s responsibility to ensure that the amended informed consent is reviewed and approved by Ora prior to submission to the governing IRB/IEC and that it is read, signed and dated by all subjects subsequently enrolled in the study as well as those currently enrolled in the study. 
If informed consent is taken under special circumstances (oral informed 
consent), then the procedures to be followed must be determined by Ora 
and/or study sponsor and provided in writing by Ora and/or study sponsor prior to the consent process. 
11.1.2 IRB Approval 
This study is to be conducted in accordance with IRB regulations (U.S. 21 CFR Part 56.103).  The Investigator must obtain appropriate IRB approval before initiating the study and re-approval at least annually. 
Only an IRB/ERC approved version of the ICF will be used. 
11.2
(WKLFDO &RQGXFW RI WKH 6WXG\
This study will be conducted in accordance with the ethical principles that originated 
with the Declaration of Helsinki. 
11.36XEMHFW &RQILGHQWLDOLW\
All personal study subject data collected a nd processed for the purposes of this study 
should be maintained by the Investigator and his/her staff with adequate precautions 
as to ensure that the confidentiality of the data in accordance with local, state, and federal laws and regulations. 
Monitors, auditors and other authorized representatives of Ora, the sponsor, the 
IRB/IEC approving this study, the Food and Drug Administration (FDA), the Department of Health and Human Services (DHHS), other domestic government agencies, and other foreign regulatory agencies will be granted direct access to the study subjectâ€™s original medical and study records for verification of the data and/or 
clinical trial procedures.  Access to this information will be permitted to the aforementioned individuals to the extent permitted by law. 
A report of the results of this study may be published or sent to the appropriate health 
authorities in any country in which the investigational product may ultimately be marketed, but the subjectâ€™s identity will not be disclosed in these documents.
03Jul2018 CONFIDENTIAL Page  of 
    Clinical label texts for the primary pa ckaging (glass vials) and secondary 
packaging (clinical kits) meet applicable regulatory requirements and include 
the statement â€œCaution: New Drug -Limited by Federal Law to Investigational 
Use.â€     
11.5.2 Storage of Investigational Product 
Investigational drug must be stored in a secure area of the investigative site, 
accessible only to Investigator or designees, at room temperature between 15Â° - 25Â°C (59-77Â°F).  The investigational product will be administered only to subjects entered into the clinical study, in accordance with the conditions specified in this protocol.  All invest igational drugs will be returned to 
inventory after use. 
11.5.3 Accountability of Investigational Product 
The investigational product is to only be administered by the principal Investigator or his/her named sub Investigator(s), and is to only be used in accordance with this protocol.  The investigational product must only be distributed to subjects properly qualified under this protocol to receive investigational product. 
The Investigator must keep an accurate accounting of the investigational 
product received from the supplier.  This includes the amount of investigational product administered to subjects and the amount returned or disposed upon the completion of the study.  A detailed inventory must be completed for the investigational product. 
11.5.4 Return or Disposal of Investigational Product 
All investigational products will be ret urned to the sponsor or their designee 
or destroyed.  The return or disposal of investigational product will be specified in writing. 
11.6
5HFRUGLQJ RI 'DWD RQ 6RXUFH 'RFXPHQWV DQG (OHFWURQLF &DVH
5HSRUWV )RUPV H&5)V
The Investigator is responsible for ensuring that study data is completely and 
accurately recorded on each subjectâ€™s source document, eCRF and all study-related material.  All study data should also be attributable, legible, contemporaneous, and original.  Recorded datum should only be corrected in a manner that does not 
obliterate, destroy, or render illegible the previous entry (e.g., by drawing a single line 
through the incorrect entry and writing the revision next to the corrected data).  An individual who has corrected a data entry should make clear who made the correction and when, by adding to the correction his/her initials as well as the date of the correction. 
03Jul2018 CONFIDENTIAL Page  of 
    11.7+DQGOLQJ RI %LRORJLFDO 6SHFLPHQV
Not applicable 
11.83XEOLFDWLRQV
Authorship and manuscript composition will reflect cooperation among all parties 
involved in the study. Authorship will be established before writing the manuscript.  Ora and the study sponsor will have the final decision regarding the manuscript and publication. 
5()(5(1&(6
Francois J. and Goes F. Ultrasonic study of the effect of different miotics on the eye components. 
Ophthalmologica Basel 1977;175(6):328-338. 
Gilmartin B, Amer A, Ingleby S. Reversal of tropicamide mydriasis with single instillations of 
pilocarpine can induce substantial pseudo-myopia in young adults. Ophthalmic & Physiological Optics 1995;15(5):475-479. 
Helmholtz, H.v. Uber die akkommodation des auges. A. v. Graefeâ€™s Arch. Klin. Ophthalmol. 
1855;1, 1 â€“74.
Holden B, Fricke T, Ho S, Wong R, Schlenther G, CronjeÂ´ S, Burnett A, Papas E, Naidoo K, Frick K. Global vision impairment due to uncorr ected presbyopia. Archives of Ophthalmology 
2008;126(12):1731-1739. 
Ostrin, L.A. and Glasser, A Edinger-Westphal and pharmacologically stimulated accommodative 
refractive changes and lens and ciliary process movements in rhesus monkeys. Experimental Eye 
Research 2007;84: 302-313. 
Randazzo A, Nizzola F, Rossetti L, Orzalesi N, Vinciquerra P. Pharmacological management of 
night vision disturbances after refractive surgery â€“ Results of a randomized clinical trial. J Cataract 
Refract Surg 2005;31(9): 1764-1772.  
Romano, J. H. Double-blind cross-over comparis on of aceclidine and pilocarpine in open-angle 
glaucoma. British Journal of Ophthalmology 1970;54: 510-521.
Scarcelli, G., Kim, P., and Yun, S.H. In vivo measurement of age-related stiffening in the 
crystalline lens by brillouin optical microscopy. Biophysical Journal 2011;101: 1539-1545. 
Truscott, R. J. Presbyopia. Emerging from a blur towards an understanding of the molecular 
basis for this most common eye condition. Ex perimental Eye Research 2009;88: 241-247. 
03Jul2018 CONFIDENTIAL Page  of 
    $SSHQGL[  +DQGOLQJ RI %LRORJLFDO 6SHFLPHQV
Not applicable 
03Jul2018 CONFIDENTIAL Page  of 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 

03Jul2018 CONFIDENTIAL Page  of 
    $SSHQGL[ 
 6SRQVRU DQG 2UD $SSURYDOV
3URWRFRO7LWOH A Single-Center, Double-Masked Evaluation of the Efficacy and 
Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
3URWRFRO1XPEHU PRX100.FDAIIb
)LQDO'DWH 03Jul2018
This clinical study protocol was subject to critica l review and has been approved by the sponsor.  
The following personnel contributed to writing and/or approving this protocol. 
Signed
Signed
